

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Weggeman et al.

Serial No.: To be assigned

Filed: August 23, 2006

For: VIRUS PURIFICATION METHODS

Confirmation No.: To be assigned

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2578-7869US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV826301234US

Date of Deposit with USPS: August 23, 2006

Person making Deposit: Brett Hooke

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

10/590427

AP9 Rec'd PCT/PTO 23 AUG 2006

Attorney Docket No.: 2578-7869US

U.S. Patent Documents

| <u>U.S. Patent No.</u> | <u>Publication Date</u> | <u>Patentee</u> |
|------------------------|-------------------------|-------------------------|
| US - 5,559,099 | 09-24-1996 | Wickham et al. |
| US - 5,789,390 | 08-04-1998 | Descamps et al. |
| US - 5,837,511 | 11-17-1998 | Falck-Pedersen et al. |
| US - 5,837,520 | 11-17-1998 | Shabram et al. |
| US - 5,840,565 | 11-24-1998 | Lau |
| US - 5,846,782 | 12-08-1998 | Wickham et al. |
| US - 5,851,806 | 12-22-1998 | Kovesdi et al. |
| US - 5,891,690 | 04-06-1999 | Massie |
| US - 5,948,410 | 09-07-1999 | Van Scharrenburg et al. |
| US - 5,965,541 | 10-12-1999 | Wickham et al. |
| US - 5,981,225 | 11-09-1999 | Kochanek et al. |
| US - 5,994,106 | 11-30-1999 | Kovesdi et al. |
| US - 5,994,128 | 11-30-1999 | Fallaux et al. |
| US - 5,994,134 | 11-30-1999 | Giroux et al. |
| US - 6,008,036 | 12-28-1999 | Fanget et al. |
| US - 6,020,191 | 02-01-2000 | Scaria et al. |
| US - 6,040,174 | 03-21-2000 | Imler et al. |
| US - 6,113,913 | 09-05-2000 | Brough et al. |
| US - 6,146,873 | 11-14-2000 | Kistner et al. |
| US - 6,168,941 | 01-02-2001 | Liu et al. |
| US - 6,168,944 | 01-02-2001 | Condon et al. |
| US - 6,261,823 | 07-17-2001 | Tang et al. |
| US - 6,309,650 | 10-30-2001 | Kim et al. |
| US - 6,342,384 | 01-29-2002 | Chung et al. |
| US - 6,485,958 | 11-26-2002 | Blanche et al. |
| US - 6,492,169 | 12-10-2002 | Vogels et al. |
| US - 6,537,793 | 03-25-2003 | Blanche et al. |

Attorney Docket No.: 2578-7869US

| | | |
|------------------|------------|----------------|
| US - 6,586,226 | 07-01-2003 | Carrion et al. |
| US - 2002/182723 | 12-05-2002 | Toohyon et al. |

Foreign Patent Documents

| <u>Document No.</u> | <u>Publication Date</u> | <u>Patentee</u> |
|---------------------|-------------------------|--|
| EP 1 230 354 B1 | 08-14-2002 | Cevec Pharmaceuticals GmbH |
| WO 99/41416 | 08-19-1999 | Schering Corp. |
| WO 99/12568 | 03-18-1999 | Merck & Co., Inc. |
| WO 98/39411 | 09-11-1998 | Baxter Int'l, Inc. |
| WO 98/22588 | 05-28-1998 | Introgen Therapeutics, Inc. |
| WO 97/08298 | 03-06-1997 | Genzyme Corp. |
| WO 96/26281 | 08-29-1996 | Genvec, Inc. et al. |
| WO 03/084479 | 10-16-2003 | Merck & Co., Inc. |
| WO 03/097797 | 11-27-2003 | Merck & Co., Inc. |
| WO 03/104467 | 12-18-2003 | Crucell Holland B.V. |
| WO 2004/001032 | 12-31-2003 | Crucell Holland B.V. |
| WO 03/078592 | 09-25-2003 | Cell Genesys, Inc. |
| WO 03/028632 | 04-10-2003 | Government of the U.S.A., as represented by the Secretary, Dept. of H. H. S. |
| WO 03/049763 | 06-19-2003 | Mayne Pharma PTY LTD |
| WO 02/070673 | 09-12-2002 | Schering Aktiengesellschaft |
| WO 02/44348 | 06-06-2002 | Schering Corp. |
| WO 01/77304 | 10-18-2001 | Genvec, Inc. |
| WO 02/22080 | 03-21-2002 | Merck & Co., Inc. |
| WO 00/50573 | 08-31-2000 | Transgene S.A. |
| WO 00/03029 | 01-20-2000 | Introgene B.V. |
| WO 2005/080556 | 09-01-2005 | Crucell Holland B.V. |
| WO 00/70071 | 11-23-2000 | Introgene B.V. |

Attorney Docket No.: 2578-7869US

WO 01/38362

05-31-2001

Crucell Holland B.V.

Other Documents

PCT International Preliminary Report on Patentability, PCT/ EP2005/050439,
dated July 18, 2006.

PCT International Search Report, PCT/EP 2005/050439, dated October 27, 2005.

GREEN et al., "A new Scalable Method for the Purification of Recombinant
Adenovirus Vectors," Human Gene Therapy, 1 November 2002, pp. 1921-1934, Vol. 13.

DRITTANTI et al., "Optimised helper virus-free production of high-quality
adeno-associated virus vectors," The Journal of Gene Medicine, 2001, pp. 59-71, Vol. 3.

SULLIVAN et al., "Development of a preventive vaccine for Ebola virus infection
in primates," Nature, 30 November 2000, pp. 609-609, Vol. 408.

This Information Disclosure Statement is filed within three (3) months of the filing date
of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee
pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Kelly A. Echols
Registration No. 55,911
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: August 23, 2006
KAE/alb

Enclosures: Form PTO/SB/08
Cited Non-U.S. Patent Documents
Document in ProLaw

10/590427
 IAP9 Rec'd PCT/PTO 23 AUG 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | To be assigned |
| Filing Date | August 23, 2006 |
| First Named Inventor | Weggeman et al. |
| Group Art Unit | To be assigned |
| Examiner Name | To be assigned |
| Attorney Docket Number | 2578-7869US |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
| | | Number - Kind Code ² (if known) | | | |
| | | US-5,559,099 | 09-24-1996 | Wickham et al. | |
| | | US- 5,789,390 | 08-04-1998 | Descamps et al. | |
| | | US- 5,837,511 | 11-17-1998 | Falck-Pedersen et al. | |
| | | US- 5,837,520 | 11-17-1998 | Shabram et al. | |
| | | US- 5,840,565 | 11-24-1998 | Lau | |
| | | US- 5,846,782 | 12-08-1998 | Wickham et al. | |
| | | US- 5,851,806 | 12-22-1998 | Kovesdi et al. | |
| | | US- 5,891,690 | 04-06-1999 | Massie | |
| | | US- 5,948,410 | 09-07-1999 | Van Scharrenburg et al. | |
| | | US- 5,965,541 | 10-12-1999 | Wickham et al. | |
| | | US- 5,981,225 | 11-09-1999 | Kochanek et al. | |
| | | US- 5,994,106 | 11-30-1999 | Kovesdi et al. | |
| | | US- 5,994,128 | 11-30-1999 | Fallaux et al. | |
| | | US- 5,994,134 | 11-30-1999 | Giroux et al. | |
| | | US- 6,008,036 | 12-28-1999 | Fanget et al. | |
| | | US- 6,020,191 | 02-01-2000 | Scaria et al. | |
| | | US- 6,040,174 | 03-21-2000 | Imler et al. | |
| | | US- 6,113,913 | 09-05-2000 | Brough et al. | |
| | | US- 6,146,873 | 11-14-2000 | Kistner et al. | |
| | | US- 6,168,941 | 01-02-2001 | Liu et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---|--------------------------------|---|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | | EP 1 230 354 B1 | 08-14-2002 | Cevec Pharmaceuticals GmbH | | |
| | | WO 99/41416 | 08-19-1999 | Schering Corp. | | |
| | | WO 99/12568 | 03-18-1999 | Merck & Co., Inc. | | |
| | | WO 98/39411 | 09-11-1998 | Baxter Int'l, Inc. | | |
| | | WO 98/22588 | 05-28-1998 | Introgen Therapeutics, Inc. | | |
| | | WO 97/08298 | 03-06-1997 | Genzyme Corp. | | |
| | | WO 96/26281 | 08-29-1996 | Genvec, Inc. et al. | | |
| | | WO 03/084479 | 10-16-2003 | Merck & Co., Inc. | | |
| | | WO 03/097797 | 11-27-2003 | Merck & Co., Inc. | | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

10/590427
IAP9 Rec'd PCT/PTO 23 AUG 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|-----------------|---|--------------------------|--|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| Application Number | | To be assigned | | | |
| Filing Date | | August 23, 2006 | | | |
| First Named Inventor | | Weggeman et al. | | | |
| Group Art Unit | | To be assigned | | | |
| Examiner Name | | To be assigned | | | |
| Attorney Docket Number | | 2578-7869US | | | |
| Sheet | 2 | of | 3 | | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|---|---|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | | US - 6,168,944 | 01-02-2001 | Condon et al. | |
| | | US - 6,261,823 | 07-17-2001 | Tang et al. | |
| | | US - 6,309,650 | 10-30-2001 | Kim et al. | |
| | | US - 6,342,384 | 01-29-2002 | Chung et al. | |
| | | US - 6,485,958 | 11-26-2002 | Blanche et al. | |
| | | US - 6,492,169 | 12-10-2002 | Vogels et al. | |
| | | US - 6,537,793 | 03-25-2003 | Blanche et al. | |
| | | US - 6,586,226 | 07-01-2003 | Carion et al. | |
| | | US - 2002/182723 | 12-05-2002 | Toohyon et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | | WO 03/104467 | 12-18-2003 | Crucell Holland B.V. | | |
| | | WO 2004/001032 | 12-31-2003 | Crucell Holland B.V. | | |
| | | WO 03/078592 | 09-25-2003 | Cell Genesys, Inc. | | |
| | | WO 03/028632 | 04-10-2003 | Government of the U.S.A., as represented by the Secretary, Dept. of H. H. S. | | |
| | | WO 03/049763 | 06-19-2003 | Mayne Pharma PTY LTD | | |
| | | WO 02/070673 | 09-12-2002 | Schering Aktiengesellschaft | | |
| | | WO 02/44348 | 06-06-2002 | Schering Corp. | | |
| | | WO 01/77304 | 10-18-2001 | Genvec, Inc. | | |
| | | WO 02/22080 | 03-21-2002 | Merck & Co., Inc. | | |
| | | WO 00/50573 | 08-31-2000 | Transgene S.A. | | |
| | | WO 00/03029 | 01-20-2000 | Introgene B.V. | | |
| | | WO 2005/080556 | 09-01-2005 | Crucell Holland B.V. | | |
| | | WO 00/70071 | 11-23-2000 | Introgene B.V. | | |
| | | WO 01/38362 | 05-31-2001 | Crucell Holland B.V. | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

10/590427
IAP9 Rec'd PCT/PTO 23 AUG 2006

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | To be assigned |
| Filing Date | August 23, 2006 |
| First Named Inventor | Weggeman et al. |
| Group Art Unit | To be assigned |
| Examiner Name | To be assigned |
| Attorney Docket Number | 2578-7869US |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | | PCT International Preliminary Report on Patentability, PCT/ EP2005/050439, dated July 18, 2006. | |
| | | PCT International Search Report, PCT/EP 2005/050439, dated October 27, 2005. | |
| | | GREEN et al., "A new Scalable Method for the Purification of Recombinant Adenovirus Vectors," Human Gene Therapy, 1 November 2002, pp. 1921-1934, Vol. 13. | |
| | | DRITTANTI et al., "Optimised helper virus-free production of high-quality adeno-associated virus vectors," The Journal of Gene Medicine, 2001, pp. 59-71, Vol. 3. | |
| | | SULLIVAN et al., "Development of a preventive vaccine for Ebola virus infection in primates," Nature, 30 November 2000, pp. 609-609, Vol. 408. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

+